Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment

References

• Healy D. The Creation of Psychopharmacology. Harvard University Press, MA, USA (2002).
   Google Scholar
• Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science127(3296), 471 (1958).
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. The action of dopamine on the arterial blood pressure of the guinea-pig. Br. J. Pharmacol. Chemother.13(1), 91–94 (1958).
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord.17(3), 501–508 (2002).
   PubMedGoogle Scholar
• Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature180(4579), 244–245 (1957).
   PubMed Web of Science ®Google Scholar
• Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol. Psychiatry32(1), 1–17 (1992).
   PubMed Web of Science ®Google Scholar
• Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse1(2), 133–152 (1987).
   PubMed Web of Science ®Google Scholar
• Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov. Disord.23(Suppl. 3), S497–S508 (2008).
   PubMed Web of Science ®Google Scholar
• Iversen SD, Iversen LL. Dopamine: 50 years in perspective. Trends Neurosci.30(5), 188–193 (2007).
   PubMed Web of Science ®Google Scholar
• Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol.67(1), 53–83 (2002).
   PubMed Web of Science ®Google Scholar
• Standaert DG, Galanter JM. Pharmacology of dopaminergic neurotransmission. In: Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Golan DE, Tashjian AJ Jr, Armstrong EJ, Armstrong AW (Eds). Lippincott Williams & Wilkins, NY, USA, 185–206 (2008).
   Google Scholar
• Kupfermann I. Modulatory actions of neurotransmitters. Annu. Rev. Neurosci.2, 447–465 (1979).
   PubMed Web of Science ®Google Scholar
• Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialities (CPS). Canadian Pharmacists Association, Ottawa, Canada (2010).
   Google Scholar
• Goto Y, Grace AA. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int. Rev. Neurobiol.78, 41–68 (2007).
   PubMed Web of Science ®Google Scholar
• Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol.78, 1–39 (2007).
   PubMed Web of Science ®Google Scholar
• Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog. Brain Res.172, 117–140 (2008).
   PubMed Web of Science ®Google Scholar
• Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex8(4), 321–345 (1998).
   PubMed Web of Science ®Google Scholar
• Beauregard M, Ferron A, Descarries L. Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: an iontophoretic study. Neuroscience47(3), 613–619 (1992).
   PubMedGoogle Scholar
• Studler JM, Kitabgi P, Tramu G, Herve D, Glowinski J, Tassin JP. Extensive co-localization of neurotensin with dopamine in rat meso–cortico–frontal dopaminergic neurons. Neuropeptides11(3), 95–100 (1988).
   PubMed Web of Science ®Google Scholar
• Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson’s disease: a major hypokinetic basal ganglia disorder. J. Neural Transm.106(5–6), 443–476 (1999).
   PubMed Web of Science ®Google Scholar
• Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox. Res.10(3–4), 167–179 (2006).
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Fredholm BB, Bloch B, Le Moine C. Co-stimulation of D1/D5 and D2 dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons. Neuroscience98(4), 749–757 (2000).
   PubMedGoogle Scholar
• Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature353(6340), 164–167 (1991).
   PubMed Web of Science ®Google Scholar
• Capper-Loup C, Canales JJ, Kadaba N, Graybiel AM. Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization. J. Neurosci.22(14), 6218–6227 (2002).
   PubMed Web of Science ®Google Scholar
• Scornaiencki R, Cantrup R, Rushlow WJ, Rajakumar N. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness. Int. J. Neuropsychopharmacol.12(9), 1195–1208 (2009).
   PubMedGoogle Scholar
• Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci.19(4), 136–140 (1998).
   PubMedGoogle Scholar
• Martina M, Bergeron R. D1 and D4 dopaminergic receptor interplay mediates coincident G protein-independent and dependent regulation of glutamate NMDA receptors in the lateral amygdala. J. Neurochem.106(6), 2421–2435 (2008).
   PubMedGoogle Scholar
• Hu JL, Liu G, Li YC, Gao WJ, Huang YQ. Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Mol. Brain,3, 20 (2010).
   PubMedGoogle Scholar
• Jardemark K, Marcus MM, Shahid M, Svensson TH. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse64(11), 870–874 (2010).
   PubMed Web of Science ®Google Scholar
• Li YC, Liu G, Hu JL, Gao WJ, Huang YQ. Dopamine D1 receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons. J. Neurochem114(1), 62–73 (2010).
   PubMedGoogle Scholar
• Cho DI, Quan W, Oak MH, Choi HJ, Lee KY, Kim KM. Functional interaction between dopamine receptor subtypes for the regulation of c-fos expression. Biochem. Biophys. Res. Commun.357(4), 1113–1118 (2007).
   PubMedGoogle Scholar
• George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology117(2), 690–697 (1985).
   PubMed Web of Science ®Google Scholar
• McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol. Cell Endocrinol.36(3), 201–209 (1984).
   PubMedGoogle Scholar
• Seeman P, Schwarz J, Chen JF et al. Psychosis pathways converge via D2high dopamine receptors. Synapse60(4), 319–346 (2006).
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T, Ko F. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse49(4), 209–215 (2003).
   PubMedGoogle Scholar
• Willeit M, Ginovart N, Kapur S et al. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol. Psychiatry59(5), 389–394 (2006).
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res.204(1), 32–66 (2009).
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A, Mizrahi R, Agid O et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology34(4), 1078–1086 (2009).
   PubMed Web of Science ®Google Scholar
• McCormick PN, Kapur S, Reckless G, Wilson AA. Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. Synapse63(11), 998–1009 (2009).
   PubMedGoogle Scholar
• Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience41(1), 1–24 (1991).
   PubMed Web of Science ®Google Scholar
• Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet.40(7), 827–834 (2008).
   PubMed Web of Science ®Google Scholar
• Elvevag B, Weinberger DR. Introduction: genes, cognition and neuropsychiatry. Cogn. Neuropsychiatry14(4–5), 261–276 (2009).
   PubMedGoogle Scholar
• Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell. Physiol. Biochem.20(6), 687–702 (2007).
   PubMed Web of Science ®Google Scholar
• Tan HY, Callicott JH, Weinberger DR. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn. Neuropsychiatry14(4–5), 277–298 (2009).
   PubMedGoogle Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull.35(3), 549–562 (2009).
   PubMed Web of Science ®Google Scholar
• Deniker P. From chlorpromazine to tardive dyskinesia (brief history of neuroleptics). Psychiatr. J. Univ. Ott.14(1), 253–2259. (1989).
   PubMedGoogle Scholar
• Deniker P. The neuroleptics: a historical survey. Acta Physiol. Scand.82, 83–87 (1990).
   Google Scholar
• Remington G, Kapur S. The pharmacology of typical and atypical antipsychotics. In: Drug Induced Movement Disorders. Factor SA, Lang A, Weiner WJ (Eds). Blackwell Futura, MA, USA, 55–71 (2005).
   Google Scholar
• Carlsson A, Lindqvist, M. Effect of chlorpormazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouses brain. Acta Pharmicol. Toxicol. (Copenh.),20, 140–144 (1963).
   PubMedGoogle Scholar
• Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc.32(2), 200–205 (1973).
   PubMedGoogle Scholar
• Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature261(5562), 717–719 (1976).
   PubMed Web of Science ®Google Scholar
• Van Rossum J. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuro-psychopharmacologicum (CINP). Brill H, Coyle J, Deniker P, Hippius H, Bradley P (Eds). Excerptica Medica, Amsterdam, The Netherlands, 321–329 (1967).
   Google Scholar
• Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy14(5), 543–560 (1994).
   PubMed Web of Science ®Google Scholar
• Singh MM, Kay SR. A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. Psychopharmacologia43(2), 115–121 (1975).
   PubMedGoogle Scholar
• FDA approves clozapine for treatment of schizophrenia; careful monitoring required. Hosp. Community Psychiatry40(12), 1310 (1989).
   PubMedGoogle Scholar
• Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol.7(Suppl. 1), S1–S5 (2004).
   PubMedGoogle Scholar
• Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry49(7), 538–544 (1992).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry157(4), 514–520 (2000).
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry33(4), 227–235 (1993).
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J. Clin. Psychopharmacol.18(4), 305–310 (1998).
   PubMed Web of Science ®Google Scholar
• Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry159(1), 133–135 (2002).
   PubMed Web of Science ®Google Scholar
• Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J. Psychopharmacol.22(2 Suppl.), 12–19 (2008).
   PubMedGoogle Scholar
• Wolkin A, Barouche F, Wolf AP et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry146(7), 905–908 (1989).
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry50(11), 873–883 (2001).
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Ninan I. Dopamine D4 receptors and development of newer antipsychotic drugs. Fundam. Clin. Pharmacol.14(6), 529–539 (2000).
   PubMedGoogle Scholar
• Meador-Woodruff JH. Update on dopamine receptors. Ann. Clin. Psychiatry6(2), 79–90 (1994).
   PubMedGoogle Scholar
• Muir WJ, Thomson ML, McKeon P et al. Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder. Am. J. Med. Genet.105(2), 152–158 (2001).
   PubMed Web of Science ®Google Scholar
• Seeman P, Van Tol HH. Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg,6(4), 602–608 (1993).
   PubMedGoogle Scholar
• Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs – an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr. Bull.35(4), 789–797 (2009).
   PubMedGoogle Scholar
• Sunahara RK, Seeman P, Van Tol HH, Niznik HB. Dopamine receptors and antipsychotic drug response. Br. J. Psychiatry Suppl. (22), 31–38 (1993).
   PubMedGoogle Scholar
• Wong AH, Van Tol HH. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry27(7), 1091–1099 (2003).
   PubMedGoogle Scholar
• Brenner HD, Dencker SJ, Goldstein MJ et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull.16(4), 551–561 (1990).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am. J. Psychiatry141(6), 748–752 (1984).
   PubMedGoogle Scholar
• Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry45(1), 79–91 (1988).
   PubMed Web of Science ®Google Scholar
• Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol. Med.24(2), 307–316 (1994).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N. Engl. J. Med.324(11), 746–754 (1991).
   PubMed Web of Science ®Google Scholar
• Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry18(1), 39–60 (2007).
   PubMed Web of Science ®Google Scholar
• Hippius H. The history of clozapine. Psychopharmacology (Berl.),99(Suppl.), S3–S5 (1989).
   PubMedGoogle Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45(9), 789–796 (1988).
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry39(7), 789–794 (1982).
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr., Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry145(5), 578–583 (1988).
   PubMed Web of Science ®Google Scholar
• Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry137, 383–386 (1980).
   PubMed Web of Science ®Google Scholar
• Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs24(1), 9–20 (2010).
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry153(3), 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull.31(4), 910–921 (2005).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr. Bull.32(2), 250–258 (2006).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry58(2), 165–171 (2001).
   PubMed Web of Science ®Google Scholar
• Bora E, Yucel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr. Bull.36(1), 36–42 (2010).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov. Disord.24(15), 2175–2186 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Jahanshahi M, Krack P et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol.8(12), 1128–1139 (2009).
   PubMed Web of Science ®Google Scholar
• Oguru M, Tachibana H, Toda K, Okuda B, Oka N. Apathy and depression in Parkinson disease. J. Geriatr. Psychiatry Neurol.23(1), 35–41 (2010).
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Alves G, Aarsland D, Larsen JP. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry80(11), 1279–1282 (2009).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov. Disord.24(8), 1211–1216 (2009).
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson’s disease: the Norwegian ParkWest study. J. Neurol.257(2), 217–223 (2010).
   PubMed Web of Science ®Google Scholar
• Khoo TK, Burn DJ. Non-motor symptoms may herald Parkinson’s disease. Practitioner253(1721), 19–24, 12 (2009).
   PubMedGoogle Scholar
• Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov. Disord.24(16), 2391–2397 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt L, d’Arc BF, Lafargue G et al. Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain131(Pt 5), 1303–1310 (2008).
   PubMed Web of Science ®Google Scholar
• Czernecki V, Schupbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov. Disord.23(7), 964–969 (2008).
   PubMed Web of Science ®Google Scholar
• Haegelen C, Rouaud T, Darnault P, Morandi X. The subthalamic nucleus is a key structure of limbic basal ganglia functions. Med. Hypotheses72(4), 421–426 (2009).
   PubMedGoogle Scholar
• Le Jeune F, Drapier D, Bourguignon A et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology73(21), 1746–1751 (2009).
   PubMed Web of Science ®Google Scholar
• Porat O, Cohen OS, Schwartz R, Hassin-Baer S. Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.21(4), 398–405 (2009).
   PubMedGoogle Scholar
• Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry38(2), 187–190 (1981).
   PubMed Web of Science ®Google Scholar
• Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr. Res.85(1–3), 222–231 (2006).
   PubMed Web of Science ®Google Scholar
• Booij L, Van der Does AJ, Riedel WJ. Monoamine depletion in psychiatric and healthy populations: review. Mol. Psychiatry8(12), 951–973 (2003).
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry12(4), 331–359 (2007).
   PubMed Web of Science ®Google Scholar
• Boot E, Booij J, Hasler G et al. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur. J. Nucl. Med. Mol. Imaging35(7), 1350–1356 (2008).
   PubMedGoogle Scholar
• Verhoeff N, Christensen BK, Hussey D et al. Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav.74, 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Verhoeff NP, Hussey D, Lee M et al. Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans. Mol. Psychiatry7(3), 233, 322–238 (2002).
   PubMedGoogle Scholar
• Verhoeff NP, Kapur S, Hussey D et al. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology25(2), 213–223 (2001).
   PubMedGoogle Scholar
• Voruganti L, Slomka P, Zabel P et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuropsychopharmacology25(5), 642–650 (2001).
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia – findings from an in vivo SPECT study. Schizophr. Res.88(1–3), 179–186 (2006).
   PubMed Web of Science ®Google Scholar
• Riccardi P, Baldwin R, Salomon R et al. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride. Biol. Psychiatry63(2), 241–244 (2008).
   PubMedGoogle Scholar
• Bremner JD, Vythilingam M, Ng CK et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA289(23), 3125–3134 (2003).
   PubMed Web of Science ®Google Scholar
• Hasler G, Luckenbaugh DA, Snow J et al. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol. Psychiatry66(3), 201–205 (2009).
   PubMed Web of Science ®Google Scholar
• West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci.22(1), 294–304 (2002).
   PubMed Web of Science ®Google Scholar
• Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology15(1), 17–29 (1996).
   PubMed Web of Science ®Google Scholar
• Rinne JO, Portin R, Ruottinen H et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch. Neurol.57(4), 470–475 (2000).
   PubMed Web of Science ®Google Scholar
• Nobili F, Campus C, Arnaldi D et al. Cognitive–nigrostriatal relationships in de novo, drug-naive Parkinson’s disease patients: a [I-123]FP-CIT SPECT study. Mov. Disord.25(1), 35–43 (2010).
   PubMedGoogle Scholar
• Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron65(5), 585–596 (2010).
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Garcia-Sanchez C, Berthier ML et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov. Disord.15(4), 613–626 (2000).
   PubMed Web of Science ®Google Scholar
• Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson’s disease. Lancet Neurol7(10), 927–938 (2008).
   PubMed Web of Science ®Google Scholar
• Hawkins KA, Keefe RS, Christensen BK et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr. Res.105(1–3), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Jahshan C, Heaton RK, Golshan S, Cadenhead KS. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology24(1), 109–120 (2010).
   PubMed Web of Science ®Google Scholar
• Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry156(9), 1336–1341 (1999).
   PubMed Web of Science ®Google Scholar
• Belmaker RH, Wald D. Haloperidol in normals. Br. J. Psychiatry131, 222–223 (1977).
   PubMed Web of Science ®Google Scholar
• de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br. J. Clin. Pharmacol.51(2), 119–132 (2001).
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.)174(1), 3–16 (2004).
   PubMed Web of Science ®Google Scholar
• Kosaka J, Takahashi H, Ito H et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci.86(21–22), 814–818 (2010).
   PubMedGoogle Scholar
• Aleman A, EH FdH, Castner SA, Williams GV, Goldman-Rakic PS. Antipsychotics and working memory in schizophrenia. Science289(5476), 56b-58b (2000).
   PubMed Web of Science ®Google Scholar
• Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science287(5460), 2020–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia47(5), 1374–1381 (2009).
   PubMed Web of Science ®Google Scholar
• Hsieh PC, Yeh TL, Lee IH et al. Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers. J. Psychiatry Neurosci.35(2), 90–94 (2010).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A. Recent evidence for dopamine abnormalities in schizophrenia. Eur. Psychiatry17, 341–347 (2002).
   Web of Science ®Google Scholar
• Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol.78, 133–164 (2007).
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry44(7), 660–669 (1987).
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. Eur. Psychiatry17, 355–363 (2002).
   PubMedGoogle Scholar
• Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther.113(2), 296–320 (2007).
   PubMed Web of Science ®Google Scholar
• Kraepelin E. Dementia Praecox and Paraphrenia. Krieger Publishing Co., FL, USA (1971).
   Google Scholar
• Archer T. Neurodegeneration in schizophrenia. Expert Rev. Neurother.10(7), 1131–1141 (2010).
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry46(6), 729–739 (1999).
   PubMed Web of Science ®Google Scholar
• Rund BR. Is there a degenerative process going on in the brain of people with schizophrenia? Front. Hum. Neurosci.3, 36 (2009).
   PubMed Web of Science ®Google Scholar
• Waddington JL, Lane A, Scully P et al. Early cerebro-craniofacial dysmorphogenesis in schizophrenia: a lifetime trajectory model from neurodevelopmental basis to ‘neuroprogressive’ process. J. Psychiatr. Res.33(6), 477–489 (1999).
   PubMed Web of Science ®Google Scholar
• Waddington JL, Lane A, Scully PJ, Larkin C, O’Callaghan E. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease? Psychiatr. Clin. North Am.21(1), 123–149 (1998).
   PubMedGoogle Scholar
• Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull.35(3), 528–548 (2009).
   PubMed Web of Science ®Google Scholar
• Pantelis C, Yucel M, Wood SJ et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull.31(3), 672–696 (2005).
   PubMed Web of Science ®Google Scholar
• Palmer BW, Heaton SC, Jeste DV. Older patients with schizophrenia: challenges in the coming decades. Psychiatr. Serv.50(9), 1178–1183 (1999).
   PubMed Web of Science ®Google Scholar
• Bleuler E. Dementia Praecox or the Group of Schizophrenias. International Universities Press, NY, USA (1950).
   Google Scholar
• Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull.22(2), 353–370 (1996).
   PubMed Web of Science ®Google Scholar
• Holland J, Shakhmatova-Pavlova IV. Concept and classification of schizophrenia in the Soviet Union. Schizophr. Bull.3(2), 277–287 (1977).
   PubMed Web of Science ®Google Scholar
• Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can. J. Psychiatry42(2), 139–151 (1997).
   PubMed Web of Science ®Google Scholar
• Yung A. Identification and treatment of the prodromal phase of psychotic disorders: perspectives from the PACE Clinic. Early Inter. Psychiatry1, 224–235 (2007).
   Web of Science ®Google Scholar
• Addington J, Addington D. Three-year outcome of treatment in an early psychosis program. Can. J. Psychiatry54(9), 626–630 (2009).
   PubMedGoogle Scholar
• Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr. Scand.115(2), 93–100 (2007).
   PubMed Web of Science ®Google Scholar
• Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl.)202(1–3), 259–273 (2009).
   PubMed Web of Science ®Google Scholar
• Marder SR. Drug initiatives to improve cognitive function. J. Clin. Psychiatry67(Suppl. 9), 31–35 (2006).
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry197(3), 174–179 (2010).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand.115(1), 4–11 (2007).
   PubMed Web of Science ®Google Scholar
• Foussias G, Mann S, Zakzanis KK, van Reekum R, Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr. Res.115(2–3), 333–337 (2009).
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s Razor. Schizophr. Bull.36(2), 359–369 (2010).
   PubMed Web of Science ®Google Scholar
• Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs13(3), 479–495 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr. Serv.59(5), 487–496 (2008).
   PubMed Web of Science ®Google Scholar
• Hans SL, Auerbach JG, Nuechterlein KH et al. Neurodevelopmental factors associated with schizotypal symptoms among adolescents at risk for schizophrenia. Dev. Psychopathol.21(4), 1195–1210 (2009).
   PubMedGoogle Scholar
• Reichenberg A, Caspi A, Harrington H et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am. J. Psychiatry167(2), 160–169 (2010).
   PubMed Web of Science ®Google Scholar
• Sorensen HJ, Mortensen EL, Schiffman J, Reinisch JM, Maeda J, Mednick SA. Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophr. Res.118(1–3), 41–47 (2010).
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones BD. Schizophrenia as dopamine-deficiency disease. Lancet2(8080), 99–100 (1978).
   PubMedGoogle Scholar
• Bertolino A, Esposito G, Callicott JH et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am. J. Psychiatry157(1), 26–33 (2000).
   PubMed Web of Science ®Google Scholar
• Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry157(10), 1646–1651 (2000).
   PubMedGoogle Scholar
• Slifstein M, Kolachana B, Simpson EH et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry13(8), 821–827 (2008).
   PubMed Web of Science ®Google Scholar
• de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. Catechol-O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J. Cogn. Neurosci.17, 1018–1025 (2006).
   Web of Science ®Google Scholar
• Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J et al. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res.185(1–2), 286–289 (2011).
   PubMedGoogle Scholar
• Wang CY, Yu-tao X, Cai ZJ et al. Risperidone maintenance treatment in schizophrenia: a randomized controlled trial. Am. J. Psychiatry167(6), 676–685 (2010).
   PubMed Web of Science ®Google Scholar
• Pelayo-Teran JM, Perez-Iglesias R, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B. Catechol-O-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res.179(3), 291–296 (2010).
   PubMedGoogle Scholar
• Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry148(11), 1474–1486 (1991).
   PubMed Web of Science ®Google Scholar
• Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci.8(1), 137–142 (2006).
   PubMedGoogle Scholar
• Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr. Bull.28(2), 203–222 (2002).
   PubMedGoogle Scholar
• Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl.)171(2), 121–132 (2004).
   PubMed Web of Science ®Google Scholar
• Braw Y, Bloch Y, Mendelovich S et al. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr. Bull.34(3), 544–554 (2008).
   PubMed Web of Science ®Google Scholar
• Harvey PD. When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont)6(7), 12–14 (2009).
   PubMedGoogle Scholar
• Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr. Bull. DOI: 10.1093/schbul/sbq057 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ321(7273), 1371–1376 (2000).
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch. Gen. Psychiatry63(10), 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis SW, Barnes TR, Davies L et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull.32(4), 715–723 (2006).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry163(4), 600–610 (2006).
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry158(3), 360–369 (2001).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry57(6), 553–559 (2000).
   PubMed Web of Science ®Google Scholar
• Remington G, Seeman P, Shammi C, Mann S, Kapur S. ‘Extended’ antipsychotic dosing: rationale and pilot data. J. Clin. Psychopharmacol.25(6), 611–613 (2005).
   PubMed Web of Science ®Google Scholar
• Uchida H, Mamo DC, Kapur S et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry69(8), 1281–1286 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L, Fang C, Zhang A et al. The -1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol.22(8), 904–909 (2008).
   PubMed Web of Science ®Google Scholar
• Selemon LD, Begovic A, Goldman-Rakic PS, Castner SA. Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate. Neuropsychopharmacology32(4), 919–931 (2007).
   PubMedGoogle Scholar
• Selemon LD, Begovic A, Williams GV, Castner SA. Reversal of neuronal and cognitive consequences of amphetamine sensitization following chronic treatment with a D1 antagonist. Pharmacol. Biochem. Behav.96(3), 325–332 (2010).
   PubMedGoogle Scholar
• Castner SA, Vosler PS, Goldman-Rakic PS. Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex. Biol. Psychiatry57(7), 743–751 (2005).
   PubMedGoogle Scholar
• Meyer-Lindenberg A, Miletich RS, Kohn PD et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci.5(3), 267–271 (2002).
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J. Psychiatr. Res.28(3), 239–265 (1994).
   PubMed Web of Science ®Google Scholar
• Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology30(8), 1426–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology17(4), 205–229 (1997).
   PubMed Web of Science ®Google Scholar
• Lodge DJ, Grace AA. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox. Res.14(2–3), 97–104 (2008).
   PubMed Web of Science ®Google Scholar
• Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat. Rev. Neurosci.9(12), 947–957 (2008).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry65(12), 1091–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr. Bull.37(1), 108–117 (2011).
   PubMedGoogle Scholar
• Abi-Dargham A. Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry2(3), 166–171 (2003).
   PubMedGoogle Scholar
• Jay TM, Rocher C, Hotte M, Naudon L, Gurden H, Spedding M. Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. Neurotox. Res.6(3), 233–244 (2004).
   PubMed Web of Science ®Google Scholar
• Owesson-White CA, Cheer JF, Beyene M, Carelli RM, Wightman RM. Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation. Proc. Natl Acad. Sci. USA105(33), 11957–11962 (2008).
   PubMedGoogle Scholar
• Cheer JF, Aragona BJ, Heien ML, Seipel AT, Carelli RM, Wightman RM. Coordinated accumbal dopamine release and neural activity drive goal-directed behavior. Neuron54(2), 237–244 (2007).
   PubMedGoogle Scholar
• Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry63(1), 6–8 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts BM, Seymour PA, Schmidt CJ, Williams GV, Castner SA. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl.)210(3), 407–418 (2010).
   PubMedGoogle Scholar
• Chou YH, Halldin C, Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl.)185(1), 29–35 (2006).
   PubMedGoogle Scholar
• Youngren KD, Inglis FM, Pivirotto PJ et al. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology20(5), 403–412 (1999).
   PubMed Web of Science ®Google Scholar
• Chen L, Yang CR. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol.87(5), 2324–2336 (2002).
   PubMedGoogle Scholar
• Lidow MS, Elsworth JD, Goldman-Rakic PS. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther.281(1), 597–603 (1997).
   PubMed Web of Science ®Google Scholar
• Daniel DG, Weinberger DR, Jones DW et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci.11(7), 1907–1917 (1991).
   PubMedGoogle Scholar
• Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am. J. Psychiatry148(1), 78–84 (1991).
   PubMed Web of Science ®Google Scholar
• Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with D-amphetamine to model cognitive improvement in chronic schizophrenia. Hum. Psychopharmacol.25(4), 353–358 (2010).
   PubMed Web of Science ®Google Scholar
• Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. (3), CD006617 (2008).
   Google Scholar
• Grunder G, Fellows C, Janouschek H et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am. J. Psychiatry165(8), 988–995 (2008).
   PubMed Web of Science ®Google Scholar
• Janicak PG, Glick ID, Marder SR et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J. Clin. Psychiatry70(1), 25–35 (2009).
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006569 (2009).
   Google Scholar
• Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin. Ther.32(Suppl. 1), S3–S20 (2010).
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry46(10), 1388–1395 (1999).
   PubMed Web of Science ®Google Scholar
• Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem.11(3), 267–277 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta MA, Riedel WJ. Dopaminergic enhancement of cognitive function. Curr. Pharm. Des.12(20), 2487–2500 (2006).
   PubMed Web of Science ®Google Scholar
• Mu Q, Johnson K, Morgan PS et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res.94(1–3), 332–341 (2007).
   PubMed Web of Science ®Google Scholar
• Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des.15(22), 2550–2559 (2009).
   PubMed Web of Science ®Google Scholar
• Micheli F, Heidbreder C. Selective dopamine D3 receptor antagonists: a review 2001–2005. Recent Pat. CNS Drug Discov.1(3), 271–288 (2006).
   PubMedGoogle Scholar
• Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr. Bull. DOI: 10.1093/schbul/sbp149 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Yamin S, Vaddadi K. Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int. Rev. Psychiatry22(2), 138–147 (2010).
   PubMed Web of Science ®Google Scholar
• Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology34(3), 662–671 (2009).
   PubMed Web of Science ®Google Scholar
• Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry64(2), 145–152 (2008).
   PubMed Web of Science ®Google Scholar
• Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. ‘Breakthrough’ dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci.27(11), 2979–2986 (2007).
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am. J. Psychiatry156(3), 412–418 (1999).
   PubMed Web of Science ®Google Scholar
• Mezler M, Geneste H, Gault L, Marek GJ. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr. Opin. Investig. Drugs11(7), 833–845 (2010).
   PubMedGoogle Scholar
• Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs68(16), 2269–2292 (2008).
   PubMed Web of Science ®Google Scholar
• Emsley R. Drugs in development for the treatment of schizophrenia. Expert Opin. Investig. Drugs18(8), 1103–1118 (2009).
   PubMed Web of Science ®Google Scholar
• McGlashan TH. Is active psychosis neurotoxic? Schizophr. Bull.32(4), 609–613 (2006).
   PubMedGoogle Scholar
• Mihalopoulos C, Harris M, Henry L, Harrigan S, McGorry P. Is early intervention in psychosis cost-effective over the long term? Schizophr. Bull.35(5), 909–918 (2009).
   PubMed Web of Science ®Google Scholar
• Liu CC, Sheu YH, Wu SY, Lai MC, Hwu HG. Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series. Psychiatry Clin. Neurosci.64(2), 202–206 (2010).
   PubMedGoogle Scholar
• McGorry PD, Nelson B, Amminger GP et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry70(9), 1206–1212 (2009).
   PubMed Web of Science ®Google Scholar
• Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Intervention in the at-risk state to prevent transition to psychosis. Curr. Opin. Psychiatry22(2), 177–183 (2009).
   PubMedGoogle Scholar
• Walker EF, Cornblatt BA, Addington J et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res.115(1), 50–57 (2009).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Can the σ-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol. Disord. Drug Targets.8(6), 470–474 (2009).
   PubMedGoogle Scholar
• Muller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin. Neurosci.11(3), 319–332 (2009).
   PubMedGoogle Scholar
• Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci. Ther.16(1), 32–44 (2010).
   PubMed Web of Science ®Google Scholar
• Bota RG, Sagduyu K, Filin EE, Bota DA, Munro S. Toward a better identification and treatment of schizophrenia prodrome. Bull. Menninger. Clin.72(3), 210–227 (2008).
   PubMedGoogle Scholar
• Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry65(1), 28–37 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell KJ, Porteous DJ. Rethinking the genetic architecture of schizophrenia. Psychol. Med.1–14 (2010).
   Google Scholar
• Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum. Psychopharmacol.25(2), 179–186 (2010).
   PubMedGoogle Scholar
• Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry43(4), 122–129 (2010).
   PubMedGoogle Scholar
• Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry23(2), 103–111 (2010).
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Tranulis C, Gourevitch R et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol.29(1), 28–33 (2006).
   PubMed Web of Science ®Google Scholar
• Remington G. Augmenting clozapine response in treatment-resistant schizophrenia. In: Therapy-Resistant Schizophrenia. Elkis H, Meltzer HY (Eds). Karger, Basel, 129–151 (2010).
   Google Scholar
• Harvey PD, McClure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs66(11), 1465–1473 (2006).
   PubMed Web of Science ®Google Scholar
• Dean B, Scarr E. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr. Drug Targets CNS Neurol. Disord.3(3), 217–225 (2004).
   PubMedGoogle Scholar
• Hoff AL, Faustman WO, Wieneke M et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology15(4), 361–369 (1996).
   PubMed Web of Science ®Google Scholar
• Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull.32(2), 220–222 (2006).
   PubMed Web of Science ®Google Scholar
• Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol. Rev.19(3), 324–335 (2009).
   PubMed Web of Science ®Google Scholar
• Livingstone PD, Srinivasan J, Kew JN et al. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci.29(3), 539–550 (2009).
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des.16(3), 323–343 (2010).
   PubMed Web of Science ®Google Scholar
• Wallace TL, Callahan PM, Tehim A et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther.336(1), 242–253. (2011).
   PubMed Web of Science ®Google Scholar
• Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry160(4), 636–645 (2003).
   PubMed Web of Science ®Google Scholar
• Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin. Ther. Targets11(9), 1189–1206 (2007).
   PubMed Web of Science ®Google Scholar